KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Gsk (GSK) Interest & Investment Income (2016 - 2026)

Gsk has reported Interest & Investment Income over the past 18 years, most recently at $29.7 million for Q1 2026.

  • For Q1 2026, Interest & Investment Income fell 56.39% year-over-year to $29.7 million; the TTM value through Mar 2026 reached $183.3 million, down 13.43%, while the annual FY2025 figure was $224.8 million, 43.56% up from the prior year.
  • Interest & Investment Income for Q1 2026 was $29.7 million at Gsk, down from $51.9 million in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $77.0 million in Q4 2023 and troughed at $9.4 million in Q1 2022.
  • A 5-year average of $42.0 million and a median of $35.2 million in 2023 define the central range for Interest & Investment Income.
  • Biggest five-year swings in Interest & Investment Income: surged 2336.33% in 2022 and later tumbled 56.39% in 2026.
  • Year by year, Interest & Investment Income stood at $32.8 million in 2022, then skyrocketed by 134.31% to $77.0 million in 2023, then dropped by 6.6% to $71.9 million in 2024, then decreased by 27.83% to $51.9 million in 2025, then tumbled by 42.83% to $29.7 million in 2026.
  • Business Quant data shows Interest & Investment Income for GSK at $29.7 million in Q1 2026, $51.9 million in Q4 2025, and $35.1 million in Q3 2025.